Incidence of Circulating Antibodies Against Hemagglutinin of Influenza Viruses in Epidemic Season 2023/2024 in Poland
Biomolecules · 2025
DOI: 10.3390/biom15070977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Katarzyna Kondratiuk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland. Hauptthemen laut MEDLINE: Influenza, Human, Antibodies, Viral, Hemagglutinin Glycoproteins, Influenza Virus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The task is carried out from the funds of the National Health Program for 2021-2025, financed by the Minister of Health, National Health Program for 2021–2025, financed by the Minister of Health.
Abstract (Originalsprache)
The aim of this study was to determine the level of anti-hemagglutinin antibodies using the hemagglutination inhibition test (HAI) in the blood sera of patients collected during the 2023/2024 epidemic season in Poland. This data is valuable for assessing the level of population immunity to influenza viruses circulating in Poland during this epidemic season. The study material consisted of serum samples collected across the country and divided into seven age groups. The test results confirmed the presence of anti-hemagglutinin antibodies for the antigens included in the quadrivalent influenza vaccine recommended by the World Health Organization (WHO) for the 2023/2024 epidemic season: A/Victoria/4897/2022 (H1N1)pdm09, A/Darwin/9/2021 (H3N2), B/Austria/1359417/2021 (B/Victoria lineage) and B/Phuket/3073/2013 (B/Yamagata lineage). The highest values of the geometric mean (GMT = 121.0 [95% CI: 108.5–134.9]) and protective factor (70 [95% CI: 67–74]%) were recorded for the A/H3N2/influenza virus antigen. In Poland, the vaccination rate of the general population in the discussed season was only 5.52%. The obtained results can therefore be interpreted as a response of the immune system, consisting of the production of anti-hemagglutinin antibodies in patients who had previously had an infection caused by the influenza virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Virology, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.
- Department of Population Health Monitoring and Analysis, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.
ORCID-Profile: Katarzyna Kondratiuk, Aleksander Masny, Karol Szymański, Katarzyna Łuniewska, Emilia Czajkowska, Bartosz Mańkowski, Lidia B Brydak
Förderung
- The task is carried out from the funds of the National Health Program for 2021-2025, financed by the Minister of Health
- National Health Program for 2021–2025, financed by the Minister of Health
Zitieren
APA
Kondratiuk, K., Masny, A., Poznańska, A., Szymański, K., Łuniewska, K., Czajkowska, E., Mańkowski, B., & Brydak, L. B. (2025). Incidence of Circulating Antibodies Against Hemagglutinin of Influenza Viruses in Epidemic Season 2023/2024 in Poland. Biomolecules. https://doi.org/10.3390/biom15070977
Vancouver
Kondratiuk K, Masny A, Poznańska A, Szymański K, Łuniewska K, Czajkowska E, et al. Incidence of Circulating Antibodies Against Hemagglutinin of Influenza Viruses in Epidemic Season 2023/2024 in Poland. Biomolecules. 2025. doi:10.3390/biom15070977
BibTeX
@article{Kondratiuk2025,
author = {Kondratiuk, Katarzyna and Masny, Aleksander and Poznańska, Anna and Szymański, Karol and Łuniewska, Katarzyna and Czajkowska, Emilia and Mańkowski, Bartosz and Brydak, Lidia B},
title = {Incidence of Circulating Antibodies Against Hemagglutinin of Influenza Viruses in Epidemic Season 2023/2024 in Poland},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15070977}
}
EUVIMED